Jackson Laboratory Cancer Center scientists are combining human cancer genomics with mouse biology and genetics expertise to interrogate cancer in clinically meaningful ways.
Chang studies cell metabolism in tumor and immune cells, with the aim of developing new treatment approaches for cancers and immunologic diseases.
Two grants from the U.S. Department of Defense totaling $2.8 million will support Jackson Laboratory (JAX) research in one of the most deadly forms of breast cancer, known as triple-negative breast cancer.
Cancer cells hijack a mechanism that enables stem cells and germ cells to continue dividing, by reactivating telomerase. A research team led by JAX Professor Roel Verhaak reports on the discovery that, in about 35 percent of cancers, TERT promoter methylation is the key to cancer cells' success in maintaining telomeres and surviving.
JAX Assistant Professor Jennifer Trowbridge wants to know why, specifically, older people are more likely to get acute myeloid leukemia.
A cancer patient’s genetic profile may influence whether or not he or she will have a toxic response to a given chemotherapy, Jackson Laboratory researchers report in The Pharmacogenomics Journal.
The possible role of the microbiome — the bacteria, fungi and viruses living on and in us — in cancer is an intriguing area for research.
In a commentary on the paper also appearing in Nature, Jackson Laboratory Professors Karolina Palucka, M.D., Ph.D., and Jacques Banchereau, Ph.D., show how a four-pronged therapeutic strategy led to complete responses for large tumors.
The JAXCC encompasses three campuses: the headquarters and research campus in Bar Harbor, Maine, a genomics research campus in Farmington, Conn., and a facility in Sacramento, Calif specializing in preclinical model development, credentialing, and deployment in pre-and co-clinical trials.
The Bar Harbor faculty has deep expertise in mouse biology, complex genetics and computational biology that informs new experimental platforms including genetically defined mouse models bearing humanized disease alleles; improved mouse hosts for patient-derived xenografts (PDX); and novel mouse populations that model the genetic variation of human populations.
The Farmington faculty is expert in human cancer genomics; genome biology; quantitative cell biology; and computational biology and analytics, all centered on developing approaches to precision medicine.
The Sacramento campus has established a large, collaborative resource of PDX models as a major preclinical platform.